Thanks Dr T, that's a convincing explanation.
The problem is that even the largest Australian institutional super funds don't have biotech analysts, and neither do the fund managers to whom they outsource if they aren't managing in-house.
RAC - Charts & Price Action, page-332
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
0.055(4.37%) |
Mkt cap ! $218.5M | |||
| Open | High | Low | Value | Volume |
| $1.26 | $1.33 | $1.26 | $149.9K | 115.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 400 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.35 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.29 |
Change
0.055 ( 4.34 %) |
||||
| Open | High | Low | Volume | ||
| $1.26 | $1.33 | $1.26 | 12903 | ||
| Last updated 15.43pm 09/05/2024 ? | |||||
| RAC (ASX) Chart |